NasdaqGS:GILDBiotechs
Gilead (GILD) Valuation Check as New Yescarta Data Reinforces CAR T Role in Second-Line Lymphoma
Kite, a Gilead Sciences (GILD) company, just released new analysis showing its CAR T therapy Yescarta delivers consistent benefits as a second line option for difficult large B cell lymphoma cases.
See our latest analysis for Gilead Sciences.
That stronger oncology story is quietly reshaping how investors see Gilead, with the share price at $120.4 after a softer recent patch but a robust year to date share price return of 31.04 percent, backed by a 1 year total shareholder return of 33.86...